Dermatology

1. More patients in the delgocitinib cream group reported clear or almost clear skin at week 16 in both the...

1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic uveal melanoma was associated with...

1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse...

1. Intravenous ertapenem administered for a mean of 13 weeks for patients with hidradenitis suppurativa was associated with improvement in...

1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no...

1.  Amongst a cohort of breast cancer survivors, those that were treated with radiation had a higher risk of developing...

1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed...

1. Patients with pemphigus treated with first-line rituximab showed sustained complete remission rates without corticosteroids for up to 7 years...

1. Interleukin-23 inhibitors had a lower risk of developing paradoxical eczema when treated for plaque psoriasis compared to TNF inhibitors,...

1. A large majority of experts in this study came to a unified consensus on how to approach the diagnosis...